Oncology

Break new ground with our solid tumor solutions

Discover molecular signatures

Find the right workflow for your lab

QIAGEN can help your lab achieve reproducible, high-quality results – from Sample to Insight. Get accurate information faster, whether you’re a lab with limited resources or a high-throughput facility. Discover our full range of solid tumor products now.

Learn more about how we can support your lab with the right workflow

Contact specialist

Latest insights in NSCLC genomic testing

Do you want to know more about what the current genomic testing landscape for NSCLC looks like? Discover the advances and challenges in our new report.

Download now

Vote now

We want your opinion! Tell us how frequently you think mutation testing is carried out for patients with solid tumors.

In your opinion, what percentage of patients with solid tumors have predictive biomarker testing integrated into their clinical care?

Test your solid tumor knowledge

Are you ready to take the solid tumor challenge? Test your knowledge of cancer biomarkers and molecular testing.

Comprehensive solid tumor solutions

Numerous biomarkers contribute to the development of tumor growth. Identifying relevant mutations in critical genes is necessary to develop a targeted approach to cancer therapy. However, complex workflows, limited samples, long turnaround times result in high costs and can delay actionable data. Our comprehensive Sample to Insight solutions overcome these issues and support your path to oncology advancements.

Shifting the paradigm in solid tumor testing using digital PCR

Shifting the paradigm in oncohematology clinical testing using digital PCR

The complex biomarker landscape of solid tumors makes next-generation sequencing (NGS) often the preferred methodology for primary diagnosis. This is due to the capacity of NGS for extensive multiplexing and the associated increased likelihood of detecting a therapeutic target.

Digital PCR (dPCR) can enhance the patient's diagnostic journey, by providing high-precision solid tumor testing in an easy-to-use, small-footprint platform.

Learn more about dPCR for clinical testing

I was able to easily customize the QIAseq HRR Panel for the detection of HRR genes.

Dr. Nils Hartmann, Mainz University Medical Center, Germany

Explore relevant solid tumor targets

Solid tumor webinar hub

Catch up with our solid tumor webinars on demand, wherever you are, at a time that works for you.

Go to hub

Disclaimers:

QIAcuity Digital PCR instruments are sold under license from Bio-Rad Laboratories, Inc.and exclude rights for use with pediatric applications

QIAcuityDx medical device is currently under development and will be available in 20 countries in H2 2024.